Pulmozyme DNase to thin lung secretions data

Phase III results in 968 patients showed that the company's recombinant human enzyme reduced the age-adjusted risk of respiratory tract infections by 28 percent over 24 weeks in the group taking 2.5 mg once

Read the full 342 word article

How to gain access

Continue reading with a
two-week free trial.